Bmc Cancer
-
The evaluation of cervical lymph nodes is very important for patients with papillary thyroid carcinoma (PTC). Conventional ultrasound is recommended to assess the status of cervical lymph nodes but the diagnostic performance is not satisfying especially in level VI lymph nodes. Recently, shear wave elastography has shown great potential in diagnosis. Therefore, this study aimed at exploring the value of shear wave elastography in ultrasound evaluation for level VI lymph nodes in papillary thyroid carcinoma. Because Hashimoto's thyroiditis may influence the diagnostic performance, a subgroup was also analysed that included only lymph nodes from PTC without Hashimoto's thyroiditis. ⋯ Shear wave elastography can provide additional information for ultrasound evaluation of level VI lymph nodes in papillary thyroid carcinoma, especially in papillary thyroid carcinoma without Hashimoto's thyroiditis.
-
Paclitaxel induced peripheral neuropathy (PIPN) is a major debilitating side effect of paclitaxel in patients with breast cancer with no fully known mechanisms. The aim of the study was to find out the possible risk factors for PIPN. ⋯ Age, BSA and the status of PR+, should be considered as the risk factors for PIPN before commencement of chemotherapy with paclitaxel in patients with breast cancer. Older patients, those with greater BSA and PR+ patients may need closer follow up and more medical attention due to greater incidence and severity of PIPN.
-
Immune checkpoint inhibitors (ICIs) have emerged as promising therapeutic agents in non-small cell lung cancer (NSCLC). However, the duration for which ICIs should be continued remains a clinical problem. ⋯ The PFS of the PR patients was completely different from that of the SD patients. The cases with PR prior to the onset of AE tended to show a durable response after the discontinuation of PD-1/PD-L1 inhibitors.
-
Epithelial ovarian cancer is a common malignancy, with no clinically approved diagnostic biomarker. Engrailed-2 (EN2) is a homeodomain-containing transcription factor, essential during embryological neural development, which is dysregulated in several cancer types. We evaluated the expression of EN2 in Epithelial ovarian cancer, and reviewed its role as a biomarker. ⋯ The EN2 transcription factor is a novel ovarian cancer biomarker. It demonstrates prognostic value, correlating with worse Overall Survival and Progression-free Survival. It is hoped that further work will validate its use as a biomarker, and provide insight into the role of EN2 in the development, progression and spread of ovarian cancer.